The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Inclusion Criteria:

• Male or female (sex assigned at birth, inclusive of all gender identities).
• Age 18 years or above at the time of signing the informed consent.
• Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m^2) at screening.
• Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion Criteria:

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
• Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
• History of type 1 or type 2 diabetes mellitus.

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com